Skip to main
CLPT

CLPT Stock Forecast & Price Target

CLPT Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ClearPoint Neuro Inc. demonstrates a positive financial outlook, highlighted by a reported 17% growth in topline revenue and a significant reduction in cash burn for 2023. The company's strategic expansion in partnerships, particularly within the biologics segment, is expected to drive at least 20% revenue growth in 2024, further enhancing its financial performance. Additionally, the progress made in product approvals and system installations, supported by favorable clinical publications, reinforces the company's momentum heading into 2024, suggesting a strong trajectory for sustained growth and improved profitability.

Bears say

ClearPoint Neuro has demonstrated a significant reduction in cash burn throughout 2023, decreasing from $5.8 million in the first quarter to $1.2 million in the fourth quarter, indicating improved financial management. However, despite the positive trend in cash burn, the company operates in a competitive market with uncertainty regarding its ability to scale its integrated systems effectively amid potential industry challenges. Furthermore, without sustained revenue growth from both its medical device segment and its biologics partnerships, the long-term financial viability of ClearPoint Neuro remains questionable, warranting a cautious outlook on its stock.

CLPT has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearpoint Neuro Inc (CLPT) Forecast

Analysts have given CLPT a Strong Buy based on their latest research and market trends.

According to 1 analysts, CLPT has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearpoint Neuro Inc (CLPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.